Impact of DNA vector topology on non-viral gene therapeutic safety and efficacy

Current Gene Therapy

Volumn 14, Issue 4, 2014, Pages 309-329

  Sum, Chi H ^a   Wettig, Shawn ^a   Slavcev, Roderick A ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Cationic lipids; Gene therapy; Linear covalently closed (LCC) DNA minivector; Lipoplex; Non viral gene delivery; Recombinant plasmid DNA vectors; Synthetic vectors

Indexed keywords

CHITOSAN; DENDRIMER; LIPOPLEX; MINICIRCLE DNA; POLYETHYLENEIMINE; POLYLYSINE; DNA; LIPID;

ARTICLE; BACTERIOPHAGE; CHEMICAL STRUCTURE; CYTOTOXICITY; DNA VECTOR; ELECTROPORATION; ENDOCYTOSIS; HUMAN; INTERNALIZATION; MEMBRANE PERMEABILITY; MICROINJECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR LOCALIZATION SIGNAL; PARTICLE SIZE; PHASE TRANSITION; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ANIMAL; BIOLISTIC TRANSFORMATION; CHEMISTRY; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; PLASMID; PROCEDURES; VIRUS;

ANIMALS; BIOLISTICS; DNA; ELECTROPORATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIPIDS; MICROINJECTIONS; PLASMIDS; POLYETHYLENEIMINE; POLYLYSINE; TRANSFECTION; VIRUSES;

EID: 84907141468     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666140612154929     Document Type: Article

References (120)

1. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012-an update. J Gene Med 2013; 15(2): 65-77.
2. Wirth T, Parker N, Yla-Herttuala S. History of gene therapy. Gene 2013; 525: 162-9.
3. Bryant LM, Christopher DM, Giles AR, et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev 2013; 24(2): 55-64.
4. Melchiorri D, Pani L, Gasparini P, et al. Regulatory evaluation of Glybera in Europe-two committees, one mission. Nat Rev Drug Discov 2013; 12(9): 719.
5. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4(5): 346-58.
6. Somai N, Verma IM. Gene Therapy: trials and tribulations. Nat Rev Genet 2000; 1(2): 91-9.
7. Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 2009; 96: 151-7.
8. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol 2010; 11(6): 457-60.
9. Donkuru M, Badea I, Wettig S, et al. Advancing nonviral gene delivery: lipid-and surfactant-based nanoparticle design strategies. Nanomedicine 2010; 5(7): 1103-27.
10. Al-Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J 2009; 11(4): 671-81.
11. Mintzer MA, Simanek EE. Nonviral Vectors for Gene Delivery. Chem Rev 2009; 109: 259-302.
12. Seow Y, Wood MJ. Biological gene delivery vehicles: beyond viral vectors. Mol Ther 2009; 17(5): 767-77.
13. Medina-Kauwe LK, Hamm-Alvarez S. Intracellular trafficking of nonviral vectors. Gene Ther 2005; 12: 1734-51.
14. Wettig SD, Verrall RE, Foldvari M. Gemini Surfactants: A New Family of Building Blocks for Non-Viral Gene Delivery Systems. Curr Gene Ther 2008; 8: 9-23.
15. Zhang XX, McIntosh TJ, Grinstaff MW. Functional lipids and lipoplexes for improved gene delivery. Biochimie 2012; 94(1): 42-58.
16. Eliyahu H, Barenholz Y, Domb AJ. Polymers for DNA Delivery. Molecules 2005; 10: 34-64.
17. Zhang Y, Satterlee A, Huang L. In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther 2012; 20(7): 1298-304.
18. Plank C, Mechtler K, Szoka FCJ, Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther 1996; 7(12): 1437-46.
19. Wang W, Li W, Ma N, Steinhoff G. Non-Viral Gene Delivery Methods. Curr Pharm Biotechnol 2013; 14: 46-60.
20. Hsu CY, Uludag H. Nucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression. J Drug Target 2012; 20(4): 301-28.
21. Dean DA, Strong DD, Zimmer WE. Nuclear entry of nonviral vectors. Gene Ther 2005; 12: 881-90.
22. Gao X, Kim K, Liu D. Nonviral gene delivery: what we know and what is next. AAPS J 2007; 9(1): E92-104.
23. Mellot AJ, Forrest ML, Detamore MS. Physical non-viral gene delivery methods for tissue engineering. Ann Biomed Eng 2013; 41(3): 446-68.
24. Jafari M, Soltani M, Naahidi S, Karunaratne DN, Chen P. Nonviral Approach for Targeted Nucleic Acid Delivery. Curr Med Chem 2012; 19: 197-208.
25. Patil SD, Rhodes DG, Burgess DJ. DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J 2005; 7(1): E61-77.
26. Delalande A, Postema M, Mignet N, Midoux P, Pinchon C. Ultrasound and microbubble-assisted gene delivery: recent advances and ongoing challenges. Ther Deliv 2012; 3(10): 1199-215.
27. Geis NA, Katus HA, Bekeredijan R. Microbubbles as a vehicle for gene and drug delivery: current clinical implications and future persepctives. Curr Pharm Des 2012; 18: 2166-83.
28. Sirsi SR, Hernandex SL, Zielinski L, et al. Polyplex-microbubble hybrids for ultrasound-guided plasmid DNA delivery to solid tumors. J Control Release 2012; 157: 224-34.
29. Omata D, Negishi Y, Hagiwara S, et al. Bubble liposomes and ultrasound promoted endosomal escape of TAT-PEG liposomes as gene delivery carriers. Mol Pharmaceutics 2011; 8: 2416-23.
30. Stevenson DJ, Gunn-Moore FJ, Campbell P, Dholakia K. Single cell optical transfection. J R Soc Interface 2010; 7: 863-71.
31. Yao C, Zhang Z, Rahmanzadeh R, Huettmann G. Laser-based gene transfection and gene therapy. IEEE Trans Nanobioscience 2008; 7(2): 111-9.
32. Praveen BB, Stevenson DJ, Antkowiak M, Dholakia K, Gunn-Moore FJ. Enhancement and optimization of plasmid expression in femtosecond optical transfection. J Biophotonics 2011; 4: 229-35.
33. Terakawa M, Ogura M. Gene transfer into mammalian cells by use of a nanosecond pulsed laser-induced stress wave. Optics Lett 2004; 29(11): 1227-9.
34. Ogura M, Sato S, Nakanishi K, et al. In vivo targeted gene transfer in skin by the use of laser-induced stress waves. Lasers Surg Med 2004; 34: 242-8.
35. Kurita A, Matsunobu T, Satoh Y, et al. Targeted gene transfer into rat facial muscles by nanosecond pulsed laser-induced stress waves. J Biomed Opt 2011; 16(9): 098002-1-5.
36. Satoh Y, Kanda Y, Terakawa M, et al. Targeted DNA transfection into the mouse central nervous system using laser-induced stress waves. J Biomed Opt 2005; 10(6): 060501-1-3.
37. Plank C, Zelphati O, Mykhaylyk O, Antequera YS, Vlaskou D, Plank C. Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-progress and prospects. Adv Drug Deliv Rev 2011; 63(14-15): 1300-31.
38. Kami D, Takeda S, Itakura Y, et al. Application of magnetic nanoparticles to gene delivery. Int J Mol Sci 2011; 12: 3705-22.
39. Kumar A, Jena PK, Behera S, et al. Multifunctional magnetic nanoparticles for targeted delivery. Nanomedicine 2010; 6: 64-9.
40. Mykhaylyk O, Antequera YS, Vlaskou D, Plank C. Generation of magnetic nonviral gene transfer and magnetofection in vitro. Nat Protoc 2007; 2(10): 2391-411.
41. Vainuska D, Kozireva S, Karpovs A, Cistjakovs M, Bariseys M. A novel approach for nucleic acid delivery into cancer cells. Medicinia 2012; 48(6): 324-9.
42. Song HP, Yang JY, Lo SL, et al. Gene transfer using self assembled ternary complexes of cationic magnetic nanoparticles, plasmid DNA and cell penetrating Tat peptide. Biomaterials 2010; 31: 769-78.
43. Maio L, Zhang K, Qiao C, et al. Antitumor effect of human TRAIL on adenoid cystic carcinoma using magnetic nanoparticle-mediated gene expression. Nanomedicine 2013; 9(1): 141-50.
44. Prijic S, Prosen L, Cemazar M, et al. Surface modified magnetic nanoparticles for immuno-gene therapy of murine mammary adenocarcinoma. Biomaterials 2012; 33: 4379-91.
45. Zhou X, Liu B, Yu X, et al. Using magnetic force to enhance immune response to DNA vaccine. Small 2007; 3(10): 1707-13.
46. Owen J, Pankhurst Q, Stride E. Magnetic targeting and ultrasound mediated drug delivery: benefits, limitations and combination. Int J Hyperthermia 2012; 28(4): 362-73.
47. Martin ME, Rice KG. Peptide-guided Gene Delivery. AAPS J 2007; 9(1): E18-E29.
48. Patnaik S, Gupta KC. Novel polyethylenimine-derived nanoparticles for in vivo gene delivery. Expert Opin Drug Deliv 2013; 10(2): 215-28.
49. Jager M, Schubert S, Ochrimenko S, Fischer D, Schubert US. Branched and linear poly(ethylene imine)-based conjugates: synthetic modification, characterization, and application. Chem Soc Rev 2012; 41: 4755-67.
50. Elouahabi A, Ruysschaert JM. Formation and intracellular trafficking of lipoplexes and polyplexes. Mol Ther 2005; 11(3): 336-47.
51. Sonawane ND, Szoka FCJ, Verkman AS. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem 2003; 278(45): 44826-31.
52. Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 2005; 7: 657-63.
53. Xu Q, Wang C, Pack DW. Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers. Curr Pharm Des 2010; 16(21): 2350-68.
54. Huang M, Fong C, Khor E, Lim L. Transfection efficiency of chitosan vectors: Effect of polymer molecular weight and degree of deacetylation. J Control Release 2005; 106: 391-406.
55. Chen HH, Ho YP, Jiang X, et al. Quantitative comparison of intracellular unpacking kinetics of polyplexes by a model constructed from quantum dot-FRET. Mol Ther 2008; 16(2): 324-32.
56. Dutta T, Jain NK, McMillan NAJ, Parekh HS. Dendrimer nanocarriers as versatile vectors in gene delivery. Nanomedicine 2010; 6: 25-34.
57. Bielinska AU, Chen C, Johnson J, Baker Jr JR. DNA complexing with polyamidoamine dendrimers: implications for trasfection. Bioconjugate Chem 1999; 10: 843-50.
58. Chen W, Turro NJ, Tomalia DA. Using Ethidium Bromide to Probe the Interactions between DNA and Dendrimers. Langmuir 2000; 16: 15-9.
59. Wadhwa MS, Collard WT, Adami RC, McKenzie DL, Rice KG. Peptide-mediated gene delivery: influence of peptide structure on gene expression. Bioconjug Chem 1997; 8(1): 81-8.
60. Adami RC, Collard WT, Gupta SA, et al. Stability of peptidecondensed plasmid DNA formulations. J Pharm Sci 1998; 87(6): 678-83.
61. Futaki S, Ohashi W, Suzuki T, et al. Steraylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem 2001; 12(6): 1005-11.
62. Margus H, Padari K, Pooga M. Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther 2012; 20(3): 525-33.
63. Lehto T, Kurrikoff K, Langel U. Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv 2012; 9(7): 823-36.
64. Lo SL, Wang S. An endoosmolytic Tat peptide produced by incorporation of hisitidine and cystein residues as nonviral vector for DNA transfection. Biomaterials 2008; 29(15): 2408-14.
65. Srinivas R, Samanta S, Chaudhuri A. Cationic amphiphiles: promising carriers of genetic materials in gene therapy. Chem Soc Rev 2009; 38: 3326-38.
66. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 1987; 84(21): 7413-7.
67. Labas R, Beilvert F, Barteau B, et al. Nature as a source of inspiration for cationic lipid synthesis. Genetica 2010; 138: 153-68.
68. Caracciolo G, Amenitsch H. Cationic liposome/DNA complexes: from structure to interactions with cellular membranes. Eur Biophys J 2012; 41(10): 815-29.
69. Ma B, Zhang S, Jiang H, Zhao B, Lv H. Lipoplex morphologies and their influences on transfection efficiency in gene delivery. J Control Release 2007; 123(3): 184-94.
70. Ewert KK, Ahmad A, Evans HM, Safinya CR. Cationic lipid-DNA complexes for non-viral gene therapy: relating supramolecular structures to cellular pathways. Expert Opin Biol Ther 2005; 5(1): 33-53.
71. Tros de Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci 2010; 40(3): 159-70.
72. Even-Chen S, Cohen R, Barenholz Y. Factors affecting DNA binding and stability of association to cationic liposomes. Chem Phys Lipids 2012; 165(4): 414-23.
73. Safinya CR. Structures of lipid-DNA complexes: supramolecular assembly and gene delivery. Curr Opin Struct Biol 2001; 11: 440-8.
74. Nagarajan R. Molecular Packing Parameter and Surfactant Self-Assembly: The Neglected Role of the Surfactant Tail. Langmuir 2002; 18: 31-8.
75. Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 2001; 8(15): 1188-96.
76. Zuhorn IS, Engberts JB, Hoekstra D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J 2007; 36(4-5): 349-62.
77. Mochizuki S, Kanegae N, Nishina K, et al. The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine. Biochim Biophys Acta 2013; 1828(2): 412-8.
78. Ziello JE, Huang Y, Jovin IS. Cellular endocytosis and gene delivery. Mol Med 2010; 16(5-6): 222-9.
79. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006; 58(1): 32-45.
80. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin and caveolaemediated endocytosis. Biochem J 2004; 377: 159-69.
81. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8: 185-94.
82. Lin AJ, Slack NL, Ahmad A, et al. Three Dimensional Imaging of Lipid Gene-Carriers: Membrane Charge Density Controls Transfection Behavior in Lamellar Cationic Liposome-DNA Complexes. Biophysical J 2003; 84: 3307-16.
83. Xu Y, Szoka FC. Mechanism of DNA Release from Cationic Liposome/DNA Complexes Used in Cell Transfection. Biochemistry 1996; 35: 5616-23.
84. Heinrich J, Schultz J, Bosse M, et al. Linear closed mini DNA generated by the prokaryotic cleaving-joining enzyme TelN is functional in mammalian cells. J Mol Med 2002; 80(10): 648-54.
85. Yew NS, Zhao H, Wu I, et al. Reduced Inflammatory Response to Plasmid DNA Vectors by Elimination and Inhibition of Immunostimulatory CpG Motifs. Mol Ther 2000; 1(3): 255-62.
86. Takahashi Y, Nishikawa M, Takakura Y. Development of safe and effective nonviral gene therapy by eliminating CpG motifs from plasmid DNA vector. Front Biosci 2012; S4: 133-41.
87. Mayrhofer P, Schleef M, Jechlinger W. Use of minicircle plasmids for gene therapy. Methods Mol Biol 2009; 542: 87-104.
88. Yew NS, Zhao H, Przybylska M, et al. CpG-Depleted Plasmid DNA Vectors with Enhanced Safety and Long-Term Gene Expression in vivo. Mol Ther 2002; 5(6): 731-8.
89. Wolf HK, Johansson N, Thong A, et al. Plasmid CpG Depletion Improves Degree and Duration of Tumor Gene Experession Ater Intravenous Administration of Polyplexes. Pharm Res 2008; 25(7): 1654-62.
90. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008; 26(5): 549-51.
91. Gill DR, Pringle IA, Hyde SC. Progress and Prospects: The design and production of plasmid vectors. Gene Ther 2009; 16: 165-71.
92. Nafissi N, Slavcev R. Construction and characterization of an invivo linear covalently closed DNA vector production system. Microb Cell Fact 2012; 11: 154.
93. Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther 1997; 4: 1341-9.
94. Groth AC, Calos MP. Phage integrases: biology and applications. J Mol Biol 2004; 335: 667-78.
95. Dong Y, Aied A, Li J, et al. An in vitro approach for production of non-scar minicircle DNA vectors. J Biotechnol 2013; 166(3): 84-7.
96. Mayrhofer P, Blaesen M, Schleef M, Jechlinger W. Minicircle-DNA production by site specific recombination and protein-DNA interaction chromatography. J Gene Med 2008; 10: 1253-69.
97. Chen Z, He C, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003; 8(3): 495-500.
98. Kay MA, He C, Chen Z. A robust system for production of minicircle DNA vectors. Nat Biotechnol 2010; 28: 1287-9.
99. Chen ZY, Riu E, He CY, Xu H, Kay MA. Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther 2008; 16(3): 548-56.
100. Rodriguez EG. Nonviral DNA vectors for immunization and therapy: design and methods for their obtention. J Mol Med (Berl) 2004; 82(8): 500-9.
101. Schakowski F, Gorschluter M, Junghans C, et al. A novel minimalsize vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther 2001; 3(5): 793-800.
102. Schakowski F, Gorschluter M, Buttgereit P, et al. Minimal Size MIDGE Vectors Improve Transgene Expression In vivo. In vivo 2007; 21: 17-24.
103. Lopez-Fuertes L, Perez-Jimenez E, Vila-Coro AJ, et al. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 2002; 21(3-4): 247-57.
104. Wang H, Chen Z, Zhang G, et al. A novel micro-linear vector for in vitro and in vivo gene delivery and its application for EBV positive tumors. PLoS One 2012; 7(10): e47159.
105. Meinhardt F, Klassen R. Microbial Linear Plasmids Microbiology Monographs, Springer 2007: 142-60.
106. Ravin NV. Mechanisms of replication and telomere resolution of the linear plasmid prophage N15. FEMS Microbiol Lett 2003; 221(1): 1-6.
107. Ravin NV. N15: the linear phage-plasmid. Plasmid 2011; 65(2): 102-9.
108. Deneke J, Ziegelin G, Lurz R, Lanka E. Phage N15 Telomere Resolution. J Biol Chem 2002; 277(12): 10410-9.
109. Hertwig S, Klein I, Lurz R, Lanka E, Appel B. PY54, a linear plasmid prophage of Yersinia enterocolitica with covalently closed ends. Mol Microbiol 2003; 48(4): 989-1003.
110. Kreiss P, Cameron B, Rangara R, et al. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res 1999; 27(19): 3792-8.
111. Yin W, Xiang P, Li Q. Investigations of the effect of DNA size in transient transfection assay using dual luciferase system. Analytical Biochem 2005; 346: 289-94.
112. Hsu CY, Uludag H. Effects of size and topology of DNA molecules on intracellular delivery with non-viral gene carriers. BMC Biotechnol 2008; 8: 23.
113. Kamiya H, Yamazaki J, Harashima H. Size and topology of exogenous DNA as determinant factors of transgene transcription in mammalian cells. Gene Ther 2002; 9(22): 1500-7.
114. Nafissi N, Sum CH, Wettig S, Slavcev RA. Optimization of a onestep heat-inducible in vivo mini DNA vector production system. PLoS One 2014; 9(2): e89345.
115. Young JL, Benoit JN, Dean DA. Effect of a DNA nuclear targeting sequence on gene transfer andexpression of plasmids in the intact vasculature. Gene Ther 2003; 10: 1465-70.
116. Mesika A, Grigoreva, I., Zohar, M., Reich, Z. A Regulated, NFkappaB-assisted Import of Plasmid DNA into Mammalian Cell Nuclei. Mol Ther 2001; 3(5 Pt 1): 653-7.
117. Breuzard G, Tertil M, Goncalves C, et al. Nuclear delivery of NFkappaB-assisted DNA/polymer complexes: plasmid DNA quantitation by confocal laser scanning microscopy and evidence of nuclear polyplexes by FRET imaging. Nucleic Acids Res 2008; 36(12): e71.
118. Dean DA, Dean, BS, Muller S, Smith LC. Sequence Requirements for Plasmid Nuclear Import. Exp Cell Res 1999; 253: 713-22.
119. Miller AM, Dean DA. Tissue-specific and transcription factormediated nuclear entry of DNA. Adv Drug Deliv Rev 2009; 61(7-8): 603-13.
120. Nafissi N, Alqawlaq S, Foldvari M, et al. DNA Ministrings: Highly Safe and Effective Gene-Delivery Vectors. Mol Ther Nucleic Acids 2014; 3(e1).